Figure 7 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma

Le résumé fourni par la source

Concurrent CDK9 and OxPhos inhibition inhibits growth of MCL cells. A, Parental and ibrutinib-resistant MCL cell lines were treated with the indicated doses of IACS-010579 for 72 hours. Cell proliferation was assessed using a colorimetric tetrazolium-based assay. The mean ± SEM is shown. *, P < 0.05 for JeKo-1 vs. JeKo-1R comparison. B, MCL cell lines were treated with IACS-010579 at the indicated doses for 24 hours (n = 3 tested in duplicates). Apoptosis was determined by flow cytometry using Annexin V–FITC staining. *, P < 0.05 and **, P < 0.01 compared with control. C, MCL cell lines were treated with IACS-010579 and/or AZD4573 as single agents or in combination at the indicated doses for 72 hours. Cell proliferation was assessed using a colorimetric tetrazolium-based assay. The mean ± SEM is shown. *, P < 0.05 and **, P < 0.01 compared with control. D, 3D heat maps of synergy scores for cell lines treated with IACS-010759 and AZD4573 as seen in C. Tables show the combinations for each cell line with the highest ZIP synergy scores.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.